Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.42 |
| ▸ | ULK1 | O75385 | 7/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13387239 | 0.83 | PKM (0.41) | PKMULK1PTK2PTK2BCDK1 | |
| SCHEMBL3286230 | 0.81 | SYK (0.41) | PTK2SYKALDH1A1HTR2CPSEN1 | |
| SCHEMBL3280278 | 0.79 | KMT2A (0.43) | SYKHTR2CPSEN1PSEN2APH1B | |
| SCHEMBL3286256 | 0.79 | PTK2 (0.43) | ULK1PTK2PTK2BSYK | |
| SCHEMBL3285562 | 0.75 | SYK (0.41) | PTK2SYKALDH1A1HTR2C | |
| SCHEMBL3286839 | 0.72 | KMT2A (0.43) | HTR2C | |
| SCHEMBL13387229 | 0.72 | FLT3 (0.49) | SYK | |
| SCHEMBL16570846 | 0.70 | FGFR4 (0.47) | ULK1PTK2PTK2BCDK1CCNB1 | |
| SCHEMBL3286379 | 0.70 | EGFR (0.57) | PTK2CDK7SYK | |
| SCHEMBL14670736 | 0.70 | BCL6 (0.43) | PKMULK1PTK2PTK2BCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | PKM 1248/4885ULK1 656/4885PTK2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.